Giansante Carlo, Fiotti Nicola, Di Chiara Antonio, Altamura Nicola, Wasserman Stella, Fioretti Paolo, Guarnieri Gianfranco
U.C.O. Clinica Medica Generale e Terapia Medica Dipartimento di Scienze Cliniche, Morfologiche e Tecnologiche, Università degli Studi di Trieste, Strada di Fiume 447, 34149 Trieste, Italy.
J Cardiovasc Med (Hagerstown). 2007 Aug;8(8):602-7. doi: 10.2459/JCM.0b013e32802e6c28.
The present study was designed to evaluate the role of some inflammation [interleukin (IL)-1beta, soluble IL-1 receptor, IL-1 receptor antagonist (IL-1RA), high-sensitivity C-reactive protein (hsCRP) and fibrinogen], and remodeling markers [matrix metalloproteinase (MMP)-9, tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2] in patients with acute coronary syndrome (ACS; 40 patients), or chronic stable angina (CSA; 40 patients) compared to age- and sex-matched healthy controls (20 subjects).
IL-1RA, hsCRP, fibrinogen, MMP-9, and TIMP-1 plasma levels were significantly higher in patients than in controls, whereas soluble IL-1 receptor had an opposite pattern. Among patients with ACS, hsCRP plasma levels were higher in patients with non-ST segment elevation myocardial infarction (NSTEMI) than in those with unstable angina (UA). TIMP-1 plasma levels were higher in those patients with ACS who did not respond to medical therapy (non-responsive unstable angina; NR-UA). A CRP plasma level higher than 0.86 mg/dl had a 91% positive predictive value (PPV) and 63% negative predictive value for NSTEMI (odds ratio = 6.4, 95% confidence interval = 1.5-27.4). TIMP-1 plasma level higher than 21.5 ng/ml had a 100% PPV for patients with NR-UA or NSTEMI. Binary logistic analysis confirmed TIMP-1 levels as being able to predict responsiveness to therapy.
In conclusion, a different biochemical pattern characterizes ACS patients: those with NR-UA show only an increase of remodeling markers, whereas ACS patients with NSTEMI have an increase of both remodeling and inflammation markers.
本研究旨在评估某些炎症指标[白细胞介素(IL)-1β、可溶性IL-1受体、IL-1受体拮抗剂(IL-1RA)、高敏C反应蛋白(hsCRP)和纤维蛋白原]以及重塑指标[基质金属蛋白酶(MMP)-9、金属蛋白酶组织抑制剂(TIMP)-1和TIMP-2]在急性冠状动脉综合征(ACS;40例患者)或慢性稳定型心绞痛(CSA;40例患者)患者中的作用,并与年龄和性别匹配的健康对照者(20名受试者)进行比较。
患者的IL-1RA、hsCRP、纤维蛋白原、MMP-9和TIMP-1血浆水平显著高于对照组,而可溶性IL-1受体则呈现相反的模式。在ACS患者中,非ST段抬高型心肌梗死(NSTEMI)患者的hsCRP血浆水平高于不稳定型心绞痛(UA)患者。在对药物治疗无反应的ACS患者(无反应性不稳定型心绞痛;NR-UA)中,TIMP-1血浆水平较高。CRP血浆水平高于0.86mg/dl对NSTEMI的阳性预测值(PPV)为91%,阴性预测值为63%(优势比=6.4,95%置信区间=1.5-27.4)。TIMP-1血浆水平高于21.5ng/ml对NR-UA或NSTEMI患者的PPV为100%。二元逻辑分析证实TIMP-1水平能够预测治疗反应性。
总之,ACS患者具有不同的生化模式:NR-UA患者仅表现为重塑指标升高,而NSTEMI的ACS患者则同时出现重塑和炎症指标升高。